Payment overview · 2025
General Payments
$2,610.14
103 reported records · 23 companies
Healthcare provider profile · identity verified
Christopher Santo Dibello, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · NEW SMYRNA BEACH, FL · NPI 1487875977
Verified facts
What the public records show
CMS Open Payments records show Christopher Santo Dibello, M.D. received $2,610.14 in general payments during 2025 across 103 reported records.
GlaxoSmithKline, LLC. accounted for 15.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ofev by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 1204 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $406.71 | 15.6% | 29 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $361.15 | 13.8% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $275.37 | 10.6% | 12 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $234.33 | 9.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $183.16 | 7.0% | 5 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $174.07 | 6.7% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $157.76 | 6.0% | 8 | 2025 |
| Galvanize Therapeutics, Inc | Unresolved — no canonical attribution shown | $136.53 | 5.2% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $132.19 | 5.1% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $117.51 | 4.5% | 6 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $91.74 | 3.5% | 4 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $44.62 | 1.7% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $41.13 | 1.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $39.88 | 1.5% | 2 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$34.45 | 1.3% | 1 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $30.90 | 1.2% | 1 | 2025 |
| Ethicon Inc. | Unresolved — no canonical attribution shown | $25.29 | 1.0% | 1 | 2025 |
| Fisher & Paykel Healthcare Inc | Unresolved — no canonical attribution shown | $24.48 | 0.9% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $21.19 | 0.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.78 | 0.8% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $20.46 | 0.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.81 | 0.8% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $16.63 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,486.08 | 101 |
| Education | $124.06 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $493.34 | 17 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $267.84 | 22 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $197.09 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $175.30 | 6 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $174.07 | 2 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $174.07 | 2 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $174.07 | 2 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $174.07 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $161.28 | 5 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $157.76 | 8 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $138.87 | 7 | 2025 |
Source payment records
|
|||||
| ALIYA SYSTEM Normalized: aliya system |
Device | Galvanize Therapeutics, Inc | $136.53 | 3 | 2025 |
Source payment records
|
|||||
| ION Normalized: ion |
Device | INTUITIVE SURGICAL, INC. | $135.00 | 1 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $99.33 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $95.42 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $91.74 | 4 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $58.31 | 3 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $44.62 | 2 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $41.13 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $39.88 | 2 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $30.90 | 1 | 2025 |
Source payment records
|
|||||
| Monarch Platform Normalized: monarch platform |
Device | Ethicon Inc. | $25.29 | 1 | 2025 |
Source payment records
|
|||||
| FISHER & PAYKEL HEALTHCARE Normalized: fisher paykel healthcare |
Device | Fisher & Paykel Healthcare Inc | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $19.81 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $16.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 1204 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
80 | 21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
1204 | 285 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 1716 | 716 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 1280 | 419 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 1204 | 285 |
| Fluticasone Propionate | Fluticasone Propionate | 782 | 351 |
| Azelastine Hcl | Azelastine Hcl | 765 | 351 |
| Doxycycline Hyclate | Doxycycline Hyclate | 731 | 485 |
| Ipratropium Bromide | Ipratropium Bromide | 532 | 231 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 352 | 68 |
| Montelukast Sodium | Montelukast Sodium | 351 | 100 |
| Levofloxacin | Levofloxacin | 267 | 176 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 261 | 70 |
| Furosemide | Furosemide | 246 | 82 |
| Cefdinir | Cefdinir | 225 | 166 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 224 | 93 |
| Azithromycin | Azithromycin | 212 | 67 |
| Breo Ellipta | Fluticasone/Vilanterol | 191 | 50 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 182 | 51 |
| Fluconazole | Fluconazole | 154 | 108 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 150 | 49 |
| Ventolin Hfa | Albuterol Sulfate | 121 | 46 |
| Eliquis | Apixaban | 103 | 18 |
| Spiriva Respimat | Tiotropium Bromide | 103 | 27 |
| Losartan Potassium | Losartan Potassium | 101 | 29 |
| Symbicort | Budesonide/Formoterol Fumarate | 80 | 21 |
| Atorvastatin Calcium | Atorvastatin Calcium | 77 | 18 |
| Amlodipine Besylate | Amlodipine Besylate | 76 | 22 |
| Levothyroxine Sodium | Levothyroxine Sodium | 69 | 13 |
| Potassium Chloride | Potassium Chloride | 68 | 22 |
| Trazodone Hcl | Trazodone Hcl | 61 | 23 |
| Omeprazole | Omeprazole | 60 | 15 |
| Gabapentin | Gabapentin | 58 | 13 |
| Methylprednisolone | Methylprednisolone | 57 | 44 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 55 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 51 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 34 |
| Incruse Ellipta | Umeclidinium Bromide | 38 | suppressed |
| Alprazolam | Alprazolam | 37 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 37 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 19 |
| Tramadol Hcl | Tramadol Hcl | 36 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 34 | 16 |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Lisinopril | Lisinopril | 33 | suppressed |
| Famotidine | Famotidine | 32 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Nystatin | Nystatin | 32 | 15 |
| Arnuity Ellipta | Fluticasone Furoate | 28 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 28 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 27 | suppressed |
| Metformin Hcl | Metformin Hcl | 26 | suppressed |
| Simvastatin | Simvastatin | 26 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 20 | 12 |
| Jardiance | Empagliflozin | 20 | suppressed |
| Allopurinol | Allopurinol | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Ofev | Nintedanib Esylate | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | 14 |
| Modafinil | Modafinil | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 13 | suppressed |
| Xolair | Omalizumab | 13 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Dupixent Pen | Dupilumab | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Tobramycin Sulfate | Tobramycin Sulfate | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Ethambutol Hcl | Ethambutol Hcl | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,610.14 · 103 records | GlaxoSmithKline, LLC. | ACTHAR, AIRSUPRA, ALIYA SYSTEM, AVYCAZ, Arikayce, BREZTRI, Brinsupri, CHARTIS CATHETER, DUPIXENT, Da Vinci Surgical System, EMBLAVEO, FASENRA, FISHER & PAYKEL HEALTHCARE, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, ION, JASCAYD, LUMRYZ, Leqembi, Monarch Platform, NUCALA, OPSYNVI, PULMONX CHARTIS TABLET CONSOLE, SMARTVEST, TEZSPIRE, TRELEGY ELLIPTA, UPTRAVI, YUPELRI, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE, ZERBAXA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error